Figure 5.

GlcNAc treatment improves the function of dystrophic muscles in mdx mice. DMD mdx mice were treated intraperitoneally with GlcNAc (250 mg/kg bodyweight/d) for 10 d, starting 25 d after birth. Data represents the mean of n = 6, with error bars representing sd. A, B) Soleus and EDL muscles were collected on d 35 and stained with hematoxylin and eosin. The areas of muscle damage (pixels) and muscle tissues (pixels) were estimated with Photoshop software (Adobe Systems, San Jose, CA, USA), and the percentage of damage was calculated. C–H) Soleus and EDL muscles were collected on d 35, and the force-frequency curves (C, D), maximum specific force (sP₀) (E, F), and resistance to repetitive eccentric contractions [force (G, H) and percentage of initial force (I, J)] were measured. Significance compared with PBS-treated mice by 1-way ANOVA is shown. *P < 0.05, **P < 0.01.